£150 – £500

Scientific, Clinical & Regulatory Cannabinoid Conference

Event Information

Share this event

Date and Time

Location

Location

The BMA House

Tavistock Square

Bloomsbury

London

WC1H 9JP

United Kingdom

View Map

Refund Policy

Refund Policy

No Refunds

Event description
The first conference of the Centre of Medicinal Cannabis in collaboration with the National Institute for Health Research (NIHR).

About this Event

The aims of the conference are:

• Assemble leading preclinical scientists, clinical researchers, national regulators (MHRA andNICE), government bodies and cannabis-based medicinal products (CBMP) pharmaceuticalsuppliers together to align research strategies.

• Grow and stimulate CBMP pharmaceutical industry in the UK.

• Identify the implementation challenges for CBMPs clinical research.

• Educate healthcare professions.

Submitted abstracts welcome - please see the event website for details.

www.thecmcuk.org

Speaker Biographies and Lecture titles

Keynote speakers: Centre for Medicinal Cannabis

• Dr Keith Ridge is the Chief Pharmaceutical Officer at NHS England, where he is head of profession for the pharmacy professions and the principal advisor on pharmacy and medicines use.

Lecture title: TBC

• Dr Paul Chrisp BPharm PhD, Director of the Centre for Guidelines, NICE. Paul has been with NICE since March 2009, where he was responsible for setting up the Institute’s accreditation programme for guideline developers, and more recently was Programme Director of the Medicines and Technologies Programme. Before joining NICE, Paul spent over 20 years in international medical publishing and communications, focusing on evidence to aid healthcare decision making and the adoption of new medicines. Paul trained as a pharmacist and is a member of the Royal Pharmaceutical Society.

Lecture title: Cannabis based medicinal products: what does NICE say and why?

• Prof Roger Pertwee, Emeritus Professor, University of Aberdeen ‘Potential therapeutic uses of certain plant and synthetic cannabinoids revealed by their pharmacological properties’. Roger is an Honorary Fellow of the British Pharmacological Society (BPS), has served as President (twice) of the International Cannabinoid Research Society (ICRS), Chairman of the International Association for Cannabinoid Medicines (IACM), and is on the IACM (and ICRS) Board of Directors. His awards include Mechoulam Award and the Lifetime Achievement Award from the ICRS, the Wellcome Gold Medal and the IACM Special Award.

Lecture title: Potential therapeutic uses of certain plant and synthetic cannabinoids revealed by their pharmacological properties

• Prof Sir John Tooke M BCh DM DSc FRCP FRCPI FRCGP (Hon) FAcadMed (Hon) FMedSci is a clinician scientist and graduate of Oxford University who trained at Kings College London, the Karolinska Institute in Stockholm and as a Wellcome Trust Senior Lecturer at Charing Cross Medical School in London. Sir John is immediate past President of the Academy of Medical Sciences and is currently Executive Chairman of Academic Health Solutions (http://www.academichealthsolutions.com), a Company offering high-end advisory services to improve population health and wealth worldwide through harnessing academic expertise. He Chairs the Collaboration for the Advancement of Sustainable Medical Innovation, UCL, and is a Non-Executive Director on the Board of Bupa Chile for whom he chairs the Risk Committee.

Lecture title: How we best use evidence to judge the benefits and harms of medicines

Pain session

• Prof Dave Finn, Professor of Pharmacology and Therapeutics, Science Foundation Ireland Principal Investigator, Co-Founder and Co-Director of the Centre for Pain Research at NUI Galway. Professor Finn is currently President-Elect of the Irish Pain Society, and he sits on the Scientific Advisory Panel of the European College of Neuropsychopharmacology, as well as the Council of the Biomedical Sciences Section of the Royal Academy of Medicine in Ireland and the Council of Neuroscience Ireland.

Lecture title: Cannabinoids and pain: evidence from preclinical studies

• Prof Andrew Rice MD FRCP FRCA FFPMRCA FFPMCAI is Professor of Pain Research at Imperial College London, where he is active in both translational research and in clinical practice. For many years Andrew’s laboratory played a key role in elucidating the basic science of cannabinoid analgesia. Chair of the International Association of the Study of Pain task force on Cannabinoid Analgesia.

Lecture title: What is the clinical evidence for analgesic effects of cannabinoids? Outcomes from the International Association for the Study of Pain Task Force

• Professor Helen Cross, Consultant in Paediatric Neurology at GOSH

Lecture title: TBC

• Dr Evan Lewis a Paediatric Neurologist and Clinical Neurophysiologist with expertise in epilepsy, epilepsy surgery, electroencephalography (EEG), teleneurology and medical cannabis for the treatment of neurologic disorders. Dr. Lewis is the director of the Neurology Centre of Toronto (NCT) where he treats children with a variety of neurological disorders and he also treats adults for concussion, headache and epilepsy.

Lecture title: Lay of the Land: Update on the Evidence in Cannabis for Epilepsy

Cancer session

• Prof. Guillermo Velasco Ph.D. from the Department of Biochemistry and Molecular Biology at the University of Madrid, Spain

Lecture title: TBC

Mental health session

• Dr Carl Stevenson is an Associate Professor of Neuroscience at the University of Nottingham. His research interests lie in understanding the neural and neurochemical basis of learned fear and its inhibition using rodent models of clinical relevance to anxiety-related disorders.

Lecture title: The case for cannabinoids in treating mental illness: insights from animal models

Neurodegeneration session

• Prof Javier Fernández-Ruiz, Complutense University of Madrid. Prof Fernandez-Ruiz has been working during the last 37 years in diseases of the Central Nervous System, having authored 234 research articles and 42 review articles in international journals, 42 book and 5 international patents. He is currently the Principal Investigator of the “Cannabinoids and Neurological Disorders” research group at the Complutense University. Previous President of the ICRSand member of its Executive Committee (2001-2004), as well as a founding member of the Spanish Cannabinoid Research Society (SEIC) and member of its Executive Committee (2000-2013) and President during 2007-2011.

Lecture title: Towards a phytocannabinoid-based neuroprotective therapy against neurodegeneration: preclinical studies

• Professor John Zajicek trained in Medicine at Cambridge and St Mary’s Hospital in London. He completed a PhD in cell biology in Cambridge, moved to Plymouth in 1995 as a Consultant Neurologist, and took up the Chair of Clinical Neuroscience at Plymouth University. In Plymouth he was Director of the Peninsula Clinical Trials Unit, and Chair of the UK NIHR Nervous System Disorders Specialty Group. He has recently moved to the University of St Andrews, where he is Professor of Medicine. Zajicek has served on the UK MRC Neuroscience and Mental Health Board and the MRC Methodology Panel. He is particularly interested in the way we do trials for neurodegenerative diseases, has been Chief Investigator in several large multicentre randomized controlled trials, including the investigation of cannabinoid use to slow neurodegeneration. He has authored many papers on cannabinoids, multiple sclerosis and the methodology of clinical trials in neurodegeneration, including Alzheimer’s and Parkinson’s diseases.

Lecture title: Lessons from large multicentre clinical trials of cannabinoids

Speakers TBC

Share with friends

Date and Time

Location

The BMA House

Tavistock Square

Bloomsbury

London

WC1H 9JP

United Kingdom

View Map

Refund Policy

No Refunds

Save This Event

Event Saved